Skip to main
RGNX

REGENXBIO (RGNX) Stock Forecast & Price Target

REGENXBIO (RGNX) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 50%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Regenxbio is likely to continue to face high financing needs in the near future, potentially leading to share dilution for shareholders, but this is a common issue faced by many biotech companies. Additionally, the company operates in a competitive market with other gene therapy treatments already on the market. However, the company's partnerships with other biotech companies could potentially mitigate risks and costs, but external factors such as pipeline failures or management missteps could still impact the company's stock performance.

Bears say

Regenxbio is facing regulatory setbacks and competition in the gene therapy market, with a negative FDA response to their treatment RGX-121 and challenges in finding appropriate pricing models and managing partnerships. Positive 18-month data for their treatment RGX-202 has been reported, but its estimated market value of $1.64B may not be enough to offset any potential losses from other programs or partnerships. Share dilution is also a concern, which may further impact the company's financials.

REGENXBIO (RGNX) has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 50% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of REGENXBIO and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About REGENXBIO (RGNX) Forecast

Analysts have given REGENXBIO (RGNX) a Buy based on their latest research and market trends.

According to 8 analysts, REGENXBIO (RGNX) has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

REGENXBIO (RGNX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.